Switch theme
Sign up to access all valuation multiples
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
2007
3
Last FY Revenue n/a
Last FY EBITDA -$15.7M
$61.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, OKYO Pharma achieved revenue of n/a and an EBITDA of -$15.7M.
OKYO Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OKYO Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$15.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$6.7M | XXX | -$15.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$6.2M | XXX | -$16.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OKYO Pharma's stock price is $2.
OKYO Pharma has current market cap of $62.8M, and EV of $61.8M.
See OKYO Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61.8M | $62.8M | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OKYO Pharma has market cap of $62.8M and EV of $61.8M.
OKYO Pharma's trades at n/a EV/Revenue multiple, and -4.1x EV/EBITDA.
Equity research analysts estimate OKYO Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OKYO Pharma has a P/E ratio of -10.1x.
See valuation multiples for OKYO Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $62.8M | XXX | $62.8M | XXX | XXX | XXX |
| EV (current) | $61.8M | XXX | $61.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.1x | XXX | XXX | XXX |
| EV/EBIT | -9.2x | XXX | -6.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.1x | XXX | -7.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOKYO Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $5.2M for the same period.
OKYO Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OKYO Pharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OKYO Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $5.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OKYO Pharma acquired XXX companies to date.
Last acquisition by OKYO Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . OKYO Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OKYO Pharma founded? | OKYO Pharma was founded in 2007. |
| Where is OKYO Pharma headquartered? | OKYO Pharma is headquartered in United States of America. |
| How many employees does OKYO Pharma have? | As of today, OKYO Pharma has 3 employees. |
| Who is the CEO of OKYO Pharma? | OKYO Pharma's CEO is Dr. Gary S. Jacob, PhD. |
| Is OKYO Pharma publicy listed? | Yes, OKYO Pharma is a public company listed on NAS. |
| What is the stock symbol of OKYO Pharma? | OKYO Pharma trades under OKYO ticker. |
| When did OKYO Pharma go public? | OKYO Pharma went public in 2022. |
| Who are competitors of OKYO Pharma? | Similar companies to OKYO Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OKYO Pharma? | OKYO Pharma's current market cap is $62.8M |
| Is OKYO Pharma profitable? | Yes, OKYO Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
